At this time, patents prevent any company from making a generic Intermezzo (zolpidem sublingual tablet) in the United States. The first patent is scheduled to expire in February 2025, which is the earliest estimated date that a generic Intermezzo product could become available. However, new patents for specific uses or lawsuits may delay the manufacturing of a generic version of this drug.
Intermezzo® (zolpidem sublingual tablet) is a prescription sleep medication. It is unique in that it comes as a low-dose, fast-acting sublingual tablet. It is taken in the middle of the night, after a person wakes up and has difficulty getting back to sleep.
Intermezzo is made by Transcept Pharmaceuticals, Inc. It is currently under the protection of patents that prevent any generic versions of Intermezzo from being manufactured in the United States.
The first patent is set to expire in February 2025. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for new Intermezzo uses. Once the drug goes off-patent, there may be several companies that manufacture a generic Intermezzo drug.
No -- zolpidem is the active ingredient in Intermezzo (as well as a few other medications), but is not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.
Intermezzo is not interchangeable with other zolpidem medications. It is the only zolpidem medication approved for middle-of-the-night insomnia.